Stryker Corporation | Large-cap | Healthcare
377,12 US$
-0,05 %
| Stryker Stock Comparison:
Stryker vs Abbott LaboratoriesStryker vs Boston ScientificStryker vs Medtronic plcStryker vs Edwards LifesciencesStryker vs DexcomStryker vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 22,6B
Gross Profit 14,4B 63,91 %
Operating Income 4,7B 20,65 %
Net Income 3,0B 13,25 %

Balance Sheet Metrics

Total Assets 43,0B
Total Liabilities 22,3B
Shareholders Equity 20,6B
Debt to Equity 1,08

Cash Flow Metrics

Operating Cash Flow 3,3B
Free Cash Flow 3,5B

Revenue & Profitability Trend

Income Statement

Metric 2024 2023 2022 2021 2020
Revenue 22,6B 20,5B 18,4B 17,1B 14,4B
Cost of Goods Sold 8,2B 7,4B 6,9B 6,1B 5,3B
Gross Profit 14,4B 13,1B 11,6B 11,0B 9,1B
Operating Expenses 9,2B 8,5B 7,9B 7,7B 6,3B
Operating Income 4,7B 3,9B 3,0B 2,7B 2,2B
Pre-tax Income 3,5B 3,7B 2,7B 2,3B 2,0B
Income Tax 499,0M 508,0M 325,0M 287,0M 355,0M
Net Income 3,0B 3,2B 2,4B 2,0B 1,6B
EPS (Diluted) - 8,25 US$ 6,17 US$ 5,21 US$ 4,20 US$

Income Statement Trend

Balance Sheet

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 14,8B 12,5B 10,3B 10,0B 9,7B
Non-Current Assets 28,1B 27,4B 26,6B 24,6B 24,6B
Total Assets 43,0B 39,9B 36,9B 34,6B 34,3B
Liabilities
Current Liabilities 7,6B 7,9B 6,3B 4,5B 5,0B
Non-Current Liabilities 14,7B 13,4B 14,0B 15,2B 16,2B
Total Liabilities 22,3B 21,3B 20,3B 19,8B 21,2B
Equity
Total Shareholders Equity 20,6B 18,6B 16,6B 14,9B 13,1B

Balance Sheet Composition

Cash Flow Statement

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 3,0B 3,2B 2,4B 2,0B 1,6B
Operating Cash Flow 3,3B 3,1B 2,3B 2,8B 3,1B
Investing Activities
Capital Expenditures -755,0M -575,0M -588,0M -525,0M -487,0M
Investing Cash Flow -3,0B -962,0M -2,9B -859,0M -4,7B
Financing Activities
Dividends Paid -1,2B -1,1B -1,1B -950,0M -863,0M
Financing Cash Flow -525,0M -1,6B -749,0M -2,4B -11,0M
Free Cash Flow 3,5B 3,1B 2,0B 2,7B 2,8B

Cash Flow Trend

Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 50,99
Forward P/E 27,89
Price to Book 6,89
Price to Sales 6,21
PEG Ratio 27,89

Profitability Ratios

Profit Margin 12,31 %
Operating Margin 19,30 %
Return on Equity 14,26 %
Return on Assets 7,49 %

Financial Health

Current Ratio 1,64
Debt to Equity 82,92
Beta 0,93

Per Share Data

EPS (TTM) 7,40 US$
Book Value per Share 54,77 US$
Revenue per Share 60,89 US$

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
syk 144,2B 50,99 6,89 14,26 % 12,31 % 82,92
Abbott Laboratories 232,9B 17,38 4,77 30,65 % 31,89 % 27,09
Boston Scientific 147,6B 72,80 6,64 9,50 % 11,58 % 52,16
Medtronic plc 111,9B 24,17 2,33 9,51 % 13,90 % 59,09
Edwards Lifesciences 44,1B 31,05 4,35 16,51 % 75,71 % 6,86
Dexcom 32,1B 61,65 14,18 23,72 % 12,90 % 113,97

Financial data is updated regularly. All figures are in the company's reporting currency.